JWH-198

JWH-198
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B; US: Schedule I;
Identifiers
	IUPAC name (1-(2-Morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethanone;
JSmol)	Interactive image;
	SMILES C4COCCN4CCn2cc(c5ccccc25)C(=O)c3c1ccccc1c(OC)cc3;
	InChI InChI=1S/C26H26N2O3/c1-30-25-11-10-22(19-6-2-3-8-21(19)25)26(29)23-18-28(24-9-5-4-7-20(23)24)13-12-27-14-16-31-17-15-27/h2-11,18H,12-17H2,1H3 ; Key:QWHSUXWDDKWTOG-UHFFFAOYSA-N ;
	(what is this?) (verify)

JWH-198 is a drug from the

naphthoylindole families which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-198 has a binding affinity at the CB₁ receptor of 10 nM, binding around four times more tightly than the parent compound JWH-200, which has no substitution on the naphthoyl ring.^[1] It has been used mainly in molecular modelling of the cannabinoid receptors.^[2]^[3]

In the United States, all CB₁ receptor agonists of the 3-(1-naphthoyl)indole class such as JWH-198 are

Schedule I Controlled Substances.^[4]

References

PMID 15974991
.

PMID 7636873
.

PMID 9804691
.

^ 21 U.S.C. § 812: Schedules of controlled substances

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=JWH-198&oldid=1164683136"

[pmid15974991-1] PMID 15974991
.

[pmid7636873-2] PMID 7636873
.

[pmid9804691-3] PMID 9804691
.

[4] 21 U.S.C. § 812: Schedules of controlled substances

[1]

[2]

[3]

[4]

See also

References